The Filing Desk

Aquestive Therapeutics vs Verastem

Aquestive Therapeutics AQST · Verastem VSTM · Pharmaceuticals

Aquestive Therapeutics reported revenue of $44 million in fiscal 2025, 1.4 times Verastem's $31 million in fiscal 2025. Aquestive Therapeutics' revenue fell 22.6% in its latest year, and Verastem's grew 209.1%. Aquestive Therapeutics had an operating margin of -159.5%, against -550.3% at Verastem.

Side by side

Aquestive TherapeuticsVerastem
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$44M$31M
Revenue growth−22.6%209.1%
Revenue growth a year, last 5 years−0.6%−19.0%
Gross margin58.4%—
Operating margin−159.5%−550.3%
Net margin−188.1%−677.6%
Free cash flow−$53M—
Free cash flow margin−119.0%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count23.3%94.1%
Last close$3.91$8.18
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score2 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Aquestive TherapeuticsVerastem
Operating margin
Percent of revenue
Aquestive TherapeuticsVerastem
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aquestive TherapeuticsVerastem

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aquestive Therapeutics and Verastem pages.